<DOC>
	<DOCNO>NCT01565681</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability , pharmacodynamics pharmacokinetics ASKP1240 single intravenous dose escalate dose level healthy subject .</brief_summary>
	<brief_title>Study ASKP1240 After Single Intravenous Dose Escalating Dose Levels Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>The subject weigh least 50 kg , body mass index ( BMI ) 18 32 kg/m2 inclusive The female subject must nonchildbearing potential ( surgically sterile [ hysterectomy bilateral tubal ligation ] postmenopausal â‰¥ 1 year follicle stimulate hormone [ FSH ] &gt; 40 U/L ) Male subject agree sperm donation end study 90 day post dose , whichever long The subject highly likely comply protocol complete study The subject negative urine screen drug abuse , negative blood breathalyzer alcohol screen Screening clinic admission Day 1 The subject history severe allergic anaphylactic reaction The subject history consume 14 unit alcoholic beverage per week history alcoholism drug/chemical/substance abuse within past 2 year prior screen ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic check The subject supine mean systolic blood pressure &lt; 90 &gt; 160 mmHg mean diastolic blood pressure &lt; 50 &gt; 90 mmHg , pulse rate high 100 beat per min ( bpm ) , either screen clinic check ( blood pressure measurement take triplicate subject rest supine position minimum 5 minute ) The subject know positive human immunodeficiency virus ( HIV ) antibody The subject positive test hepatitis C antibody , hepatitis B virus surface antigen ( HBsAg ) The subject screen clinic check : 1. white blood cell count ( WBC ) &lt; 3.5 &gt; upper limit normal 2. absolute neutrophil count ( ANC ) &lt; 1.5 &gt; upper limit normal 3. platelet count ( PLT ) outside normal limit 4. serum creatinine , total bilirubin , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; upper limit normal 5. creatine phosphokinase ( CPK ) &gt; two time upper limit normal 6. international normalize ratio ( INR ) &gt; upper limit normal 7 . OR remain laboratory test outside normal limit consider investigator clinically significant regard remain per protocol laboratory test The subject receive vaccine within 60 day prior study drug administration The subject receive systemic immunosuppressant agent within 6 month prior study drug administration . The subject receive antibody biologic product within 6 month prior study drug administration The subject receive systemic steroid within 2 month prior study drug administration The subject treatment prescription nonprescription drug , include complementary alternative medicine ( CAM ) exclude overthecounter ( OTC ) allergy medication , nasal steroid , nasal inhaler , oral contraceptive , stable hormone replacement therapy ( HRT ; per Investigator judgment dose change expect study ) , intermittent acetaminophen , within 14 day prior study drug administration The subject receive experimental agent within 30 day ten halflives , whichever longer , prior study drug administration The subject participate another clinical trial participate another dose group current trial The subject donate significant blood loss receive transfusion blood blood product within 60 day donate plasma within 7 day prior dose The subject history heavy smoking use tobaccocontaining product nicotine nicotinecontaining product past six month prior Screening The subject history thromboembolic vascular disease especially deep vein thrombosis , pulmonary embolism varices The subject positive test tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>B cell CD40 receptor occupancy</keyword>
	<keyword>anti-CD40 monoclonal antibody</keyword>
</DOC>